Giuliana Cazetta Faller

Giuliana Cazetta Faller serves as a key procurement professional within the National Institute on Drug Abuse (NIDA), supporting the agency’s mission to advance scientific research on substance use disorders and translate findings into clinical and public health applications. She manages a diverse portfolio of research and development contracts, primarily focused on high-complexity scientific instrumentation, biotechnology innovation, and analytical laboratory services. Her acquisitions enable cutting-edge neurobiological and behavioral research, ensuring that NIDA’s funded investigators have access to state-of-the-art tools and technical expertise necessary for evidence-based discovery and intervention development. Her primary contractor relationships include leading academic medical institutions such as The McLean Hospital Corporation, the University of Maryland Baltimore, the University of Miami, the University of Pittsburgh, and the Icahn School of Medicine at Mount Sinai. These partnerships are predominantly research-driven, involving cooperative agreements and cost-reimbursable contracts for preclinical and clinical studies, instrument validation, and translational science initiatives. She consistently engages with major research universities that operate as de facto R&D hubs, fostering long-term collaborations grounded in scientific rigor and regulatory compliance. Giuliana’s procurement patterns reflect a strong preference for full and open competition, with 100% of her acquisitions issued without set-asides, indicating a focus on technical excellence and scale over socioeconomic preferences. While small business participation is not formally prioritized in her portfolio, vendors of all sizes are evaluated strictly on scientific merit, technical capability, and capacity to deliver complex research infrastructure. Her primary NAICS focus areas include 334516 for analytical laboratory instrumentation, 541714 for biotechnology R&D, and 541380 for testing laboratory services. She procures specialized equipment for neuroimaging, pharmacokinetic analysis, and behavioral assessment systems, as well as contract research services supporting drug discovery, addiction biomarkers, and therapeutic development pipelines. Her domain expertise lies at the intersection of biomedical engineering, neuropharmacology, and translational science procurement.